Sage’s PPD drug to cost $15K; Abcam shareholders vote 'yes' on Danaher deal
Plus, news about Senti Biosciences, Celest Therapeutics and Aura Biosciences:
Sage’s postpartum depression drug to cost $15K for 14 days: The company announced Tuesday that it set the wholesale acquisition cost for Zurzuvae at $15,900 for a 14-day course of treatment. The FDA this summer approved the therapy as a treatment for women with postpartum depression. Leerink analysts previously predicted that Sage would price Zurzuvae between $10,000 and $35,000.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.